EN 23


EN 23 is a new class of medicine. EN 23 isn’t actually a new discovery. It’s been around for centuries. Some scientists have suggested a natural version of it actually played a role in the emergence of human language and consciousness in early hominids.

Not until the 1950’s was it synthesized, studied, and tested on human subjects. Then it was made available only to the world’s richest and brightest people. But something of this magnitude can only be kept in the dark for so long. After all, we’re talking about a pill that can help you…

      • Enhance your memory
      • Learn a foreign language within months
      • Become physically fitter
      • Increase your confidence levels
      • Successfully treat mental health conditions , such as depression, PTSD, and addiction
      • Extend your life span by as much as twenty years
      • Stave off neurodegenerative diseases, such as Parkinson’s and Alzheimer’s

Think about it for a moment… A new drug that could make you smarter, stronger, less susceptible to neurodegenerative diseases, effectively treat nearly any mental health condition, and make you more confident and successful.

The FDA is about to sign off on EN 23. It has been said that penicillin has saved more than 200 million lives since first coming to market. EN 23 will save more. EN 23 could potentially treat an almost endless number of diseases with 60%-100% effectiveness with just a single dose.

At this very moment, scientists around the world are studying EN 23 for the treatment of Alzheimer’s disease, Anorexia, Diabetes, Smoking, Epilepsy, Obesity, Autoimmune disease, Arthritis, Chronic pain, PTSD, Parkinson’s disease, Insomnia, and Crohn’s disease.

In short, this breakthrough could be the single most efficient way to treat the most stubborn and costly diseases plaguing society. What’s particularly interesting about this treatment is that, unlike most medications prescribed for chronic pain, this one is non-addictive.

In a world where the medical community is desperate to find non-addictive painkillers, this is a very big deal. Especially when you consider that the market value for chronic pain treatments exceeds $100 billion and is expected to reach $177.34 billion by 2031.

To clarify, EN 23 isn’t just a single pill or treatment. Instead, it’s a valuable class of molecules that drastically improves brain function. To be more specific, these molecules bind to the serotonin 2a receptor, which is one of 15 specialized receptor molecules the serotonin system uses to coordinate brain activity.

When administered orally, EN 23 molecules can not only lead to extreme changes in perception, cognition, and mood, but also promote neuroplasticity. As described by psychologist Kendra Cherry, neuroplasticity is the brain’s ability to change and adapt due to experience.

Neuroplasticity is kind of an umbrella term referring to the brain’s ability to change, reorganize, and grow neutral networks. This can involve functional changes due to brain damage or structural changes due to learning. While neuroplasticity is possible without any medical assistance, as it is simply a function of biology, your ability to utilize neuroplasticity to learn, grow, or heal is still limited by genetics and environment.

Simply put, some people are just born with the right genes into the right environment. They excel in science, math, and languages. They easily grasp complex academic concepts and absorb information with great speed and agility.

However, with EN 23, genetics and environment are superfluous, because EN 23 can stimulate neuroplasticity and enable you to become smarter, healthier, and more efficient in everything you do, no matter your genetic makeup or upbringing. It can help you become more confident, more creative, and more successful in your career and your relationships.

Essentially EN 23 is like steroids for your brain and central nervous system. There are no limits to what you can accomplish when taking EN 23. There’s a mountain of research that EN 23 can treat a variety of age-related diseases that essentially keep most of us from living past 100.

The good news is that the American Medical Association approvedĀ  insurance billing codes for EN 23 after the results of Phase 3 trials were released by the FDA.

To put this in perspective consider the penicillin class of antibiotics which contain about 15 chemically related drugs. All these drugs were approved by the FDA in 1945. The approval of penicillin essentially opened the floodgates for other drugs chemically related to penicillin, and that class is now valued at nearly 9 billion dollars.

The same thing is happening with EN 23, but the value of this market will easily exceed that of penicillin because it can treat so many different types of diseases and ailments. Figuring conservatively, you’re looking at a valuation of more than 1 trillion dollars.

The introduction to the general public of EN 23 is a revolutionary development. It’s curing diseases that have long been thought to be incurable.

If the Scarecrow from the Wizard of Oz had this drug, he’d be able to compute the exact time and distance in a heartbeat to get Dorothy and the gang back to Kansas, safe and sound.